Sugi Predict

Sugi Predict / Compounds / SCHEMBL489126

SCHEMBL489126

SCHEMBL489126

CC1CCN1C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ CHRM3 P20309 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.40
▸ PREP P48147 1/20 0.40
▸ SETD7 Q8WTS6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175218 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL489128 1.00 CHRM2 (0.44) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL178721 0.89 HSD17B10 (0.52) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL357042 0.89 HSD17B10 (0.52) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL357043 0.89 HSD17B10 (0.52) CHRM2CHRM1CHRM3HSD17B10HPGD
Hydrochloric Acid SCHEMBL5783201 0.88 HSD17B10 (0.38) CHRM2CHRM1CHRM3HSD17B10HPGD
Hydrochloric Acid SCHEMBL5783202 0.88 HSD17B10 (0.38) CHRM2CHRM1CHRM3HSD17B10HPGD
SCHEMBL1202111 0.87 HPGD (0.49) HSD17B10HPGDSMN1; SMN2EPHX1PREP
SCHEMBL7005690 0.87 HPGD (0.49) HSD17B10HPGDSMN1; SMN2EPHX1PREP
SCHEMBL7002987 0.87 HPGD (0.49) HSD17B10HPGDSMN1; SMN2EPHX1PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118271285-A Azetidine-containing amide derivative, preparation method and application thereof 贵州大学 2024-07-02 — — CN claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US claimed
EP-4651872-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-11-26 — — EP disclosed
CN-120058698-A Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-05-30 — — CN disclosed
CN-119912478-A Amino heteroaryl macrocyclic compounds, preparation method and application thereof 北京鞍石生物科技股份有限公司 2025-05-02 — — CN disclosed
CN-118019532-B Azetidine and pyrrolidine PARP1 inhibitors and uses thereof 新特拉有限公司 2025-03-18 — — CN disclosed
US-20250042881-A1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-02-06 — — US disclosed
CN-116969923-B Heteroaryl amino compounds, methods of preparation and use thereof 北京鞍石生物科技股份有限公司 2024-07-30 — — CN disclosed
WO-2024155601-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-07-25 — — WO disclosed
CN-118271285-A Azetidine-containing amide derivative, preparation method and application thereof 贵州大学 2024-07-02 — — CN disclosed
CN-118239937-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 — — CN disclosed
US-7094790-B2 Fused bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES (US) 2006-08-22 — — US disclosed
US-20060142325-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands ABBVIE INC. 2006-06-29 — — US disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 — — WO disclosed
EP-1490043-A2 SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS Merck & Co., Inc. (US) 2004-12-29 — — EP disclosed
US-20040248899-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands ABBVIE INC. 2004-12-09 — — US disclosed
US-20040224953-A1 e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. ABBOTT LABORATORIES 2004-11-11 — — US disclosed
US-20040224952-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES 2004-11-11 — — US disclosed
WO-2003082190-A2 SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2003-10-09 — — WO disclosed
EP-0310918-A2 Peptide-like amino-acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1989-04-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042881-A1 CCR6 RECEPTOR MODULATORS CCR6, CCR1, CCR4 CHRM2 756/4885CHRM1 1040/4885CHRM3 299/4885
US-20040248899-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH1 CHRM2 136/4885CHRM1 111/4885CHRM3 44/4885
US-20040224953-A1 e.g., 4-{2-[2-(2-(R)-Methyl-pyrrolidin-1-yl)-ethyl]-benzothiazol-5-yl}-benzonitrile; useful for treating conditions and disorders related to memory and cognition processes, neurological processes, cardiovascular function, and body weight. HRH4, HRH3, HRH2 CHRM2 98/4885CHRM1 63/4885CHRM3 113/4885
US-20060142325-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH2 CHRM2 118/4885CHRM1 204/4885CHRM3 30/4885
US-20040224952-A1 Fused bicyclic-substituted amines as histamine-3 receptor ligands HRH3, HRH4, HRH1 CHRM2 136/4885CHRM1 111/4885CHRM3 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.